GLC Application and Review Process: Collaboration with The Global Fund

Workshop on Grant Negotiation And Implementation of TB grants

Irina Sahakyan
Technical Officer
GLC Secretariat
WHO/STB/THD

December 13, 2007
GLC Initiative

Diagram 1: The GLC Initiative
GLCI: Who is Who?

<table>
<thead>
<tr>
<th>GLC</th>
<th>GDF</th>
<th>UNITAID</th>
<th>Global Fund</th>
</tr>
</thead>
<tbody>
<tr>
<td>The GLC reviews, evaluates and monitors technical aspects of MDR-TB management programmes to ensure that programs are in compliance with WHO guidelines and to allow countries to benefit from low-price second line anti-TB drugs.</td>
<td>The GDF coordinates all procurement and delivery functions for all GLC-approved programmes, allowing negotiation of better prices for second-line anti-TB drugs by pooling the procurement needs and resources of many programmes.</td>
<td>UNITAID is an international drug purchasing facility that was established to provide long-term, sustainable and predictable funding to increase access and reduce prices of high-quality drugs and diagnostics for the treatment of HIV/AIDS, malaria and tuberculosis.</td>
<td>The Global Fund is a public-private funding mechanism that attracts, manages and disburses additional resources to fight HIV/AIDS, tuberculosis and malaria in countries in need.</td>
</tr>
</tbody>
</table>
Key Success Factors for GLC programs

- **Start small** (from pilot to national scale)

Before submitting an application to the GLC, programmes should ensure the following:

- proposed treatment is in line with the WHO guidelines
- political and administrative support for the planned activities;
- functional and quality-assured laboratory that can provide drug-susceptibility testing (DST) and that is quality assured by a supranational TB reference laboratory;
- functioning health-care facilities;
- capacity to ensure patients’ adherence to the treatment regimen under patient-centred directly observed therapy (DOT);
- functioning information and data management system.
## GLC application and review process

### Pre-application
- Needs of the programme assessed, through site visit if required
- Current capacity determined and gaps identified
- Plan for filling gaps through technical assistance developed
- Application submitted to donors to fund the gaps identified during the needs assessment

### Application Processing
- Application submitted to GLC Secretariat well before starting to treat patients
- Secretariat staff work with applicants to ensure applications are complete and supporting documents are provided

### GLC Review
- GLC reviews applications every two months or as soon as received (depending on the type of application)
- GLC members may have questions about an application or identify problems or concerns that need to be addressed before an application can be approved

### GLC Approval
- Outcomes of GLC review communicated to applicants by GLC Secretariat
- Global Drug Facility informed of approval and begins preparing for drug orders

---

*Diagram 2: The GLC Application Process*
Planning for submission of a GLC application

Apply at least 10-12 months before starting the treatment

Submit application
GLC approval
Firm order placed with IDA
Start date of patients' enrolment as in the TGF proposal

Jan  Feb  Mar  Apr  May  Jun  Jul  Aug  Sep  Oct  Nov  Dec

Review & clarifications  
Procurement
Types of applications and deadlines

- **GLC meets 6 times a year**
  - 2 meetings in person, 4 by teleconference

- **There are 6 review cycles a year with the deadlines for submission:**
  - 21 January – 20 March
  - 21 March – 20 May
  - 21 May – 20 July
  - 21 July – 20 September
  - 21 September – 20 November
  - 21 November – 20 January

- **New applications** reviewed at regular cycles

- **Expansion applications** reviewed as soon as they are received.

- **There are 2 types of applications:**
  - **Fast track** for fewer than 50 patients
  - **Regular** application for more than 50 patients
Summary of GLC activities
June 2000 – October 2007

- Meetings 45
- Applications reviewed 116
- Project sites 67
- Applications approved 95
- TGF sites approved 35
- Applications for cohort expansion approved 19
- Patients in approved projects 30,371
Map of GLC approved programs

60 GLC-approved projects in 45 countries

GLC approved projects in 49 countries
## Countries with GLC approved programs

### GF support
1. Azerbaijan
2. Bangladesh
3. Bolivia
4. Burkina Faso
5. China
6. DR Congo
7. Dominican Republic
8. Ecuador
9. Egypt
10. Georgia
11. Guatemala
12. Honduras
13. India
14. Indonesia
15. Kenya
16. Kazakhstan
17. Kyrgyzstan
18. Mongolia
19. Moldova
20. Nicaragua
21. Peru
22. Philippines
23. Paraguay
24. Romania
25. Russia
26. El Salvador
27. Timor-Leste
28. Uzbekistan

### Domestic or other donor support
1. Armenia
2. Belize
3. Costa Rica
4. Estonia
5. Guinea
6. Haiti
7. Jordan
8. Cambodia
9. Lebanon
10. Lesotho
11. Lithuania
12. Latvia
13. Mexico
14. Nepal
15. Rwanda
16. Syria
17. Tunisia
18. Vietnam
19. Ukraine
20. Uganda
21. Uruguay

*As of October 2007*
Collaboration with The Global Fund

"To help contain resistance to second-line anti-TB drugs and consistent with the policies of other international funding sources, all procurement of medications to treat MDR-TB must be conducted through the Green Light Committee (GLC)"

Third Board Meeting, 10-11 October, 2002

“The board reaffirms its decision taken at its Third Board Meeting… The Board decides that applicants… must include a cost-sharing element for Green Light Committee services. To limit transaction costs this will be defined by the secretariat in consultation with the Green Light Committee as a flat rate per grant per year that will not exceed US 50,000$ per grant per year. “

Thirteenth Board Meeting, 27-28 April, 2006
The Global Fund to Fight AIDS, Tuberculosis and Malaria
Principal recipients have access to:

A. high-level expertise on the management of MDR-TB programmes based on best available evidence and collective experience;

B. high-quality drugs to treat MDR-TB at considerably lower than market prices;

C. technical assistance through a wide network of technical partners;

D. peer support and knowledge sharing in communication with other GLC-approved programmes;

E. independent external monitoring and evaluation of programmes.
GLC collaborates with Global Fund by:

- Contributing to the Global Fund's framework of performance-based management by reviewing and monitoring the technical aspects of the TGF grants with MDR-TB component.

- Reviewing program capacity and recommending scale-up for well-performing programs.

- Procuring drugs that meet quality requirements of the WHO Good Manufacturing Practices, Global Fund quality assurance policies and GDF quality requirements.

- Facilitating coordination with technical partners that can provide technical assistance to prepare a GLC application and/or include it in the GF proposal.
What should Global Fund principal recipients do?

- Contact Fund Portfolio Manager for more information
- Submit an application to the GLC at least one year before the start of treatment and well before the Phase 2 or RCC evaluation.
- Prepare and maintain a detailed forecast and plan for second-line anti-TB drug needs throughout programme implementation;
- Pay the cost-sharing element of US$50,000 per grant per year for GLC services
- Continue fundraising for technical assistance needs
# Contacts

<table>
<thead>
<tr>
<th>For information about assistance with setting up the programme:</th>
<th>For information about GLC monitoring and evaluation missions:</th>
</tr>
</thead>
<tbody>
<tr>
<td>WHO country or regional office (<a href="http://www.who.int">www.who.int</a>)</td>
<td>GLC Secretariat (<a href="mailto:glc_secretariat@who.int">glc_secretariat@who.int</a>)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>For questions about procurement:</th>
<th>For information about technical assistance in general:</th>
</tr>
</thead>
<tbody>
<tr>
<td>GDF (<a href="mailto:gdf@who.int">gdf@who.int</a>)</td>
<td>WHO country or regional office (<a href="http://www.who.int">www.who.int</a>)</td>
</tr>
<tr>
<td>IDA (<a href="mailto:service@idafoundation.org">service@idafoundation.org</a>)</td>
<td>WHO TB Team (<a href="mailto:tbteam@who.int">tbteam@who.int</a>)</td>
</tr>
<tr>
<td></td>
<td>GLC Secretariat (<a href="mailto:glc_secretariat@who.int">glc_secretariat@who.int</a>)</td>
</tr>
</tbody>
</table>
Important documents

- Guidelines for the programmatic management of drug-resistant tuberculosis

- Instructions for applying to the GLC

- Procurement manual for projects approved by the GLC

- WHO Report 2007: Global Tuberculosis Control

- The Global Plan to Stop TB 2006-2015